Oncolytics Biotech (ONCY) Non-Current Assets (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Non-Current Assets for 18 consecutive years, with $602000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 22.62% year-over-year to $602000.0 in Q2 2026; TTM through Jun 2026 was $2.8 million, a 19.81% decrease from a year earlier, with the FY2025 full-year figure at $738000.0, down 22.99% from the prior year.
• Non-Current Assets was $602000.0 for Q2 2026 at Oncolytics Biotech, down from $738000.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.2 million in Q4 2022 and troughed at $475244.5 in Q4 2023.
• A 5-year average of $788363.7 and a median of $738000.0 in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 60.9% in 2023 and surged 97.62% in 2024, its largest moves.
• Over 5 years, Non-Current Assets stood at $1.2 million in 2022, then plunged by 60.9% to $475244.5 in 2023, then surged by 97.62% to $939194.1 in 2024, then dropped by 21.42% to $738000.0 in 2025, then decreased by 18.43% to $602000.0 in 2026.
• The last three Non-Current Assets figures came in at $602000.0 (Q2 2026), $738000.0 (Q4 2025), and $730994.8 (Q3 2025), per Business Quant data.